Olumiant (Baricitinib)

To Patients
Intervention Type
Oral Drug
Funder Type
Organization | University

Drug Details

Olumiant (Baricitinib) is a type of drug known as a janus kinase, or JAK, inhibitor, which generally works by blocking proteins that play a role in inflammation. 

More Information

On November 19, 2020, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >